首页> 外文OA文献 >Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers
【2h】

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

机译:融合后呼吸道合胞病毒融合蛋白F糖蛋白(RSV F)免疫引起高中和抗体滴度的免疫结构基础

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Respiratory syncytial virus (RSV), the main cause of infant bronchiolitis, remains a major unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates based on a chief RSV neutralization antigen, the fusion (F) glycoprotein, have foundered due to problems with stability, purity, reproducibility, and potency. Crystal structures of related parainfluenza F glycoproteins have revealed a large conformational change between the prefusion and postfusion states, suggesting that postfusion F antigens might not efficiently elicit neutralizing antibodies. We have generated a homogeneous, stable, and reproducible postfusion RSV F immunogen that elicits high titers of neutralizing antibodies in immunized animals. The 3.2-Å X-ray crystal structure of this substantially complete RSV F reveals important differences from homology-based structural models. Specifically, the RSV F crystal structure demonstrates the exposure of key neutralizing antibody binding sites on the surface of the postfusion RSV F trimer. This unanticipated structural feature explains the engineered RSV F antigen's efficiency as an immunogen. This work illustrates how structural-based antigen design can guide the rational optimization of candidate vaccine antigens.
机译:尽管有40多年的疫苗研究,但呼吸道合胞病毒(RSV)是婴儿毛细支气管炎的主要病因,仍然是未满足疫苗的主要需求。由于稳定性,纯度,可重复性和效力方面的问题,基于主要RSV中和抗原,融合(F)糖蛋白的候选疫苗已经失效。相关的副流感F糖蛋白的晶体结构显示融合前和融合后状态之间的构象变化很大,表明融合后F抗原可能无法有效地引起中和抗体。我们已经产生了均质,稳定且可重现的融合后RSV F免疫原,可在免疫动物中引发高滴度的中和抗体。这种基本完整的RSV F的3.2-ÅX射线晶体结构揭示了与基于同源性的结构模型的重要区别。具体而言,RSV F晶体结构证明了融合后RSV F三聚体表面上关键的中和抗体结合位点的暴露。这种意想不到的结构特征解释了工程RSV F抗原作为免疫原的效率。这项工作说明了基于结构的抗原设计如何可以指导候选疫苗抗原的合理优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号